GSK site is set to become science campus

Abstract

GlaxoSmithKline aims to sell almost one-third of its 370,000 m 2 R&D site in Stevenage, England, so that the land can be transformed into a biotech science campus. GSK says the plan could unlock up to $470 million of private investment and create up to 5,000 skilled jobs this decade. GSK hopes detailed planning for the campus will begin in 2022. A number of other organizations are already at the site, including the UK government’s Cell and Gene Therapy Catapult and some biotech start-ups.